Bank of New York Mellon
ANIP icon

Bank of New York Mellon’s ANI Pharmaceuticals ANIP Stock Holding History

Bank of New York Mellon’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-5,000
Closed -$322K – 4314
2017
Q4 		$322K Buy
+5,000
New +$311K ﹤0.01% 3772

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of New York Mellon's ANIP Position: Q2 2026 in Review

Bank of New York Mellon increased its ANI Pharmaceuticals (ANIP) stake by 6.8% in Q2 2026, buying an estimated $609K and bringing the position to 118,597 shares worth $9.82M. The position accounts for ﹤0.01% of the portfolio, ranked #2040.

Bank of New York Mellon first reported a position in ANIP in Q2 2014 and has held it in 49 quarters since. The position peaked at $12.8M in Q3 2016. 307 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

  • Bank of New York Mellon held 118,597 shares of ANI Pharmaceuticals worth $9.82M as of Q2 2026.
  • Bank of New York Mellon bought 7,596 ANI Pharmaceuticals shares in Q2 2026, an estimated $609K.
  • ANI Pharmaceuticals made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #2040 holding.
  • Bank of New York Mellon first reported a position in ANI Pharmaceuticals in Q2 2014 and has held it in 49 quarters since.
  • Bank of New York Mellon's ANI Pharmaceuticals position peaked at $12.8M in Q3 2016.
  • 307 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.